Humacyte price to book ratio HUMA

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: 3.9×
6-year median: 9.4×
Against its 6-year history: 23rd; percentile: 0 is its lowest day, 100 its highest
6-year range: 1.8× to 82.1×
Peer median: 2.1×

Humacyte's price to book ratio is 3.9× as of Oct 23, 2026.

That is below its 6-year median of 9.4×, lower than on 77% of days in the last 6 years.

Over that time it ranged from 1.8× in Dec 2022 to 82.1× in Oct 2025.

The median for 10 healthcare stocks of a similar size is 2.1×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.9×	3.6×	75.7×
2025	52.0×	9.1×	82.1×
2024	36.0×	7.3×	41.3×
2023	8.0×	2.0×	8.7×
2022	1.8×	1.8×	8.8×
2021	9.8×	9.8×	36.8×
2020	26.1×	25.2×	26.1×

Against its peers

Companies in Healthcare nearest Humacyte's size, closest first, today.

Company	Price to book ratio
HUMAHumacyte	3.9×
KEQUKewaunee Scientific	1.3×
ICCCImmucell	3.0×
LFVNLifevantage	2.2×
PDEXPro DEX	4.2×
PLXProtalix BioTherapeutics	2.9×
NATRNatures Sunshine Products	1.3×
ELMDElectromed	4.1×
SPROSpero Therapeutics	1.5×
UTMDUtah Medical Products	1.9×
APTAlpha Pro Tech	0.9×
Peer median	2.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Humacyte

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.